PENG Block vs Fascia Iliaca Block for Emergency Department Analgesia in Hip Fractures

September 27, 2024 updated by: Santi Di Pietro, Fondazione IRCCS Policlinico San Matteo di Pavia

Pericapsular Nerve Group (PENG) Block Versus Fascia Iliaca (FIB) Block for Emergency Department Analgesia in Hip Fractures: A Randomised Controlled Trial.

Pain management is a crucial aspect of the care of hip fracture patients. Patients with poorly controlled pain have an increased risk of delirium, long-term functional impairment, and remain hospitalized longer. Today, to relieve hip fracture pain, fascia iliaca block is routinely performed in the emergency department in addition to other pain medications administered by vein or by mouth. Several studies have questioned the analgesic efficacy of this block, suggesting the superiority of the newer PENG block. The purpose of this multicenter, randomized study is to compare the analgesic efficacy of PENG block versus fascia iliaca block, hypothesizing the superiority of the new approach over the gold standard. Participants will be blindly assigned in a 1:1 ratio to the study or control group, recruited from the Emergency Departments of IRCCS Policlinico San Matteo and Colchester Hospital (UK).

The main outcome is represented by the reduction of pain after the two blocks, measured as %SPID (percentage of "pain intensity difference"), a value derived from VAS scale measurements in the first hour post-procedure. Secondly, we will evaluate the proportion of patients with satisfactory pain control, the amount of opioids used and the safety profile of the two approaches.

Study Overview

Study Type

Interventional

Enrollment (Actual)

64

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Lombardia
      • Pavia, Lombardia, Italy, 27100
        • Emergency Department, IRCCS San Matteo University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age >18
  • Capacity to understand the aim of the study, the potential benefits and side-effects of the procedures
  • Capacity to provide consent
  • Capacity to provide a self-assessment of pain using the written VAS Scale
  • Confirmed radiological diagnosis of hip fractures (including subcapitate, transcervical, intertrochanteric and perthrocanteric fractures)
  • Moderate or severe worst pain (visual analogue scale, VAS >40 mm) (at rest or dynamic)

Exclusion Criteria:

  • Known hypersensitivity to local anaesthetics
  • Confirmed radiological diagnosis of subtrochanteric or diaphyseal femur fractures
  • Hemodynamic instability
  • Known diagnosis of severe cognitive impairment
  • Dementia and/or delirium (defined by a 4AT score ≥ 2)
  • Lack of capacity to provide consent and to understand the aim of the study
  • BMI>35
  • Body weight < 40 Kg
  • Prior hip surgery on the same fracture side
  • Mild worst pain (visual analogue scale, VAS < 40 mm) (at rest or dynamic)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: PENG block: Study group
Patients enrolled in the study group will receive a PENG block with 20 mL of 0,375% levobupivacaine with 4 mg of dexamethasone. The block will be performed with the patient in a supine position using an 18-gauge, 90 mm needle, inserted with an in-plane lateral to medial approach. Operators will use the original technique described by Girón-Arango L et al. The aim of this block is to inject the local anaesthetic between the psoas tendon and the iliopubic eminence. We will instruct operators to routinely use a curvilinear probe (2-6 MHz) or a linear probe (4-16 MHz) in particularly lean or cachectic patients.
Patients of study group will receive PENG block with 20 mL of 0,375% levobupivacaine with 4 mg of dexamethasone
Other: Infrainguinal fascia iliaca block: Control group

Patients allocated in the control group will receive an infrainguinal fascia iliaca block with 30 mL of 0,25 % levobupivacaine with 4 mg of dexamethasone, using an 18-gauge, 90 mm needle, inserted with an in-plane lateral to medial approach.

The probe (linear 4-16 MHz) is placed transversely at the inguinal crease to identify the femoral artery, femoral nerve, iliopsoas muscle and the fascia iliaca over the psoas muscle. Moving the probe laterally the sartorius muscle and the anterior inferior iliac spine (AIIS) can be identified. After skin disinfection the needle is inserted placing the tip beneath the fascia iliaca at the lateral third of a line between the AIIS and pubic tubercle. Correct needle placement is confirmed by separation of the fascia iliaca from the iliopsoas muscle upon injection, with local anaesthetic spreading towards the FN medially and the iliac crest laterally.

Patients of control group will receive an infrainguinal fascia iliaca block with 30 mL of 0,25 % levobupivacaine with 4 mg of dexamethasone

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain relief over the 60-minutes following either block measured as the percentage of summed pain-intensity difference (%SPID)
Time Frame: Outcome assessed within 60 minutes following the block (PENG or FIB)
Pain relief over the 60-minutes following either block measured as the percentage of summed pain-intensity difference (%SPID) (derived from V AS measurement at T0-T1- T2-T3-T4 as described above)
Outcome assessed within 60 minutes following the block (PENG or FIB)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
33% SPID 33% (33%SPID)
Time Frame: Outcome assessed within 60 minutes following the block (PENG or FIB)
Number of patients who achieve a percentage of summed pain-intensity difference of 33% (33%SPID)
Outcome assessed within 60 minutes following the block (PENG or FIB)
50%SPID
Time Frame: Outcome assessed within 60 minutes following the block (PENG or FIB)
Number of patients who achieve a percentage of summed pain-intensity difference of 50% (50%SPID)
Outcome assessed within 60 minutes following the block (PENG or FIB)
Quantity of opioids
Time Frame: Outcome assessed within 60 minutes following the block (PENG or FIB)
Quantity of opioids (milligrams of morphine) administered in the first 60 minutes following either block
Outcome assessed within 60 minutes following the block (PENG or FIB)
Adverse events
Time Frame: Outcome assessed within 60 minutes following the block (PENG or FIB)
Occurrence of adverse events including nausea or vomiting, hypotension, respiratory depression (hypoxia or hypopnea), local anaesthetic toxicity syndrome (LAST syndrome) during ED stay (post-block). Adverse event will be described, and their incidence will be presented with 95% CI and compared with Fisher test.
Outcome assessed within 60 minutes following the block (PENG or FIB)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Santi Di Pietro, MD, PhD, IRCCS San Matteo Foundation - University of Pavia

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 30, 2022

Primary Completion (Actual)

August 16, 2024

Study Completion (Actual)

August 16, 2024

Study Registration Dates

First Submitted

May 7, 2022

First Submitted That Met QC Criteria

May 7, 2022

First Posted (Actual)

May 11, 2022

Study Record Updates

Last Update Posted (Actual)

October 1, 2024

Last Update Submitted That Met QC Criteria

September 27, 2024

Last Verified

September 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hip Fractures

Clinical Trials on Pericapsular nerve Group Block

Subscribe